• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Remdesivir for COVID-19 in short supply

News
Article

HHS says supply could run out by the end of this month.

The U.S. government's current supply of remdesivir will run out at the end of this month, CNN reported.

The amount of people who need the medication outnumbered the supply by a 2-to-1 ratio, according to The Wall Street Journal. Gilead Sciences and the Department of Health and Human Services distributed remdesivir for between 40,000 and 74,000 hospitalized patients.

Related: Top 3 COVID-19 stories this week

The government’s last shipment of remdesivir will go out the week of June 29, Robert Kadlec, MD, assistant secretary for preparedness and response at HHS, told CNN.

"Right now, we're waiting to hear from Gilead what is their expected delivery availability of the drug as we go from June to July," Kadlec said. "We're kind of not in negotiations, but in discussions with Gilead as they project what the availability of their product will be,” Kadlec said.

Related: FDA: Fraudulent COVID-19 medical products abound

"Whatever the supply may be, there may not be enough for everyone who may need it,” he added.

However, the government has been working to help Gilead "with some of their supply chain challenges in terms of raw materials and being able to accelerate the process,” Kadlec told CNN.

Gilead said it expects to have more than 500,000 remdesivir treatment courses available by October, and more than a million by December.

Read more: COVID-19 vaccines could be ready this year, plus other top news

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.